These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 27672277

  • 21. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T.
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
    [Abstract] [Full Text] [Related]

  • 22. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
    Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N.
    Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
    [Abstract] [Full Text] [Related]

  • 23. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.
    Antivir Ther; 2011 Oct; 16(7):959-68. PubMed ID: 22024511
    [Abstract] [Full Text] [Related]

  • 24. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.
    Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Bekki S, Kugiyama Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Ichikawa T, Nakao K, Yatsuhashi H.
    PLoS One; 2015 Oct; 10(6):e0129053. PubMed ID: 26070204
    [Abstract] [Full Text] [Related]

  • 25. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
    Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, Yang JF, Lin ZY, Chen SC, Wang LY, Dai CY, Huang JF, Chuang WL, Yu ML.
    J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
    [Abstract] [Full Text] [Related]

  • 26. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K, Sinn DH, Gwak GY, Cho HC, Jung SH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.
    Gut Liver; 2016 Sep 15; 10(5):796-802. PubMed ID: 27114418
    [Abstract] [Full Text] [Related]

  • 27. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.
    Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N.
    Hepatology; 2010 Aug 15; 52(2):518-27. PubMed ID: 20683951
    [Abstract] [Full Text] [Related]

  • 28. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.
    Eur J Gastroenterol Hepatol; 2013 Jul 15; 25(7):798-805. PubMed ID: 23395996
    [Abstract] [Full Text] [Related]

  • 29. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
    Honda T, Ishigami M, Masuda H, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Katano Y, Goto H.
    J Gastroenterol Hepatol; 2015 Feb 15; 30(2):321-8. PubMed ID: 25091027
    [Abstract] [Full Text] [Related]

  • 30. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2011 Jun 15; 83(6):1016-22. PubMed ID: 21503914
    [Abstract] [Full Text] [Related]

  • 31. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN.
    Int J Cancer; 2011 May 15; 128(10):2344-52. PubMed ID: 20669224
    [Abstract] [Full Text] [Related]

  • 32. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
    Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P.
    J Hepatol; 2010 May 15; 52(5):652-7. PubMed ID: 20346533
    [Abstract] [Full Text] [Related]

  • 33. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
    Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A.
    J Hepatol; 2010 Feb 15; 52(2):220-7. PubMed ID: 20036025
    [Abstract] [Full Text] [Related]

  • 34. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
    Ye X, Li C, Zu X, Lin M, Liu Q, Liu J, Xu G, Chen Z, Xu Y, Liu L, Luo D, Cao Z, Shi G, Feng Z, Deng H, Liao Q, Cai C, Liao DF, Wang J, Jin J, Cao D.
    Hepatology; 2019 Jun 15; 69(6):2489-2501. PubMed ID: 30672601
    [Abstract] [Full Text] [Related]

  • 35. Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.
    Kunimoto H, Ikeda K, Sorin Y, Fujiyama S, Kawamura Y, Kobayashi M, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.
    Oncology; 2016 Jun 15; 90(3):167-75. PubMed ID: 26901157
    [Abstract] [Full Text] [Related]

  • 36. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
    Torres-Mena JE, Salazar-Villegas KN, Sánchez-Rodríguez R, López-Gabiño B, Del Pozo-Yauner L, Arellanes-Robledo J, Villa-Treviño S, Gutiérrez-Nava MA, Pérez-Carreón JI.
    Dig Dis Sci; 2018 Apr 15; 63(4):934-944. PubMed ID: 29383608
    [Abstract] [Full Text] [Related]

  • 37. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T, Osaka Liver Forum.
    Clin Gastroenterol Hepatol; 2014 Jul 15; 12(7):1186-95. PubMed ID: 24321207
    [Abstract] [Full Text] [Related]

  • 38. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T.
    J Viral Hepat; 2014 May 15; 21(5):357-65. PubMed ID: 24716638
    [Abstract] [Full Text] [Related]

  • 39. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
    Dohmen K, Kawano A, Takahashi K, Shigematsu H, Tanaka H, Haruno M, Yanagita K, Ichiki Y, Mori T, Hayashida K, Shimoda S, Ishibashi H, Nomura H.
    Hepatogastroenterology; 2013 May 15; 60(128):2034-8. PubMed ID: 24719946
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.